Corvus Pharmaceuticals (CRVS) Cash & Current Investments (2015 - 2026)

Corvus Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $236.7 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 4635.23% year-over-year to $236.7 million in Q1 2026; TTM through Mar 2026 was $236.7 million, a 4635.23% increase from a year earlier, with the FY2025 full-year figure at $56.8 million, up 9.21% from the prior year.
• Cash & Current Investments advanced to $236.7 million in Q1 2026 per CRVS's latest filing, from $56.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $236.7 million in Q1 2026 and bottomed at $2.9 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $14.7 million (2025), against an average of $31.9 million.
• Across the five-year window, Cash & Current Investments sank 79.26% in 2022 and surged 4635.23% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $13.2 million in 2022, then decreased by 4.1% to $12.6 million in 2023, then surged by 311.76% to $52.0 million in 2024, then advanced by 9.21% to $56.8 million in 2025, then jumped by 317.12% to $236.7 million in 2026.
• Per Business Quant, the three latest CRVS Cash & Current Investments figures stand at $236.7 million (Q1 2026), $56.8 million (Q4 2025), and $2.9 million (Q3 2025).